12th Annual Outsourcing in Clinical Trials UK & Ireland 2025

Welcome to 12th annual Outsourcing in Clinical Trials UK and Ireland 2025

10 - 11

June

2025
  • Hilton Park Lane, London, UK
  • Complimentary
  • Why attend?
  • Agenda
  • Advisory Board
  • Speakers
  • Plan Your Visit
  • Event Gallery
  • 2025 Sponsors
  • Media Centre
  • Why partner?
  • Resources
  • Contact Us
close

Why attend?

WHAT TO EXPECT FOR 2025?

This exclusive event brings together attendees from established pharma, large and small, alongside with biopharmaceutical companies and gives opportunity to dive into the operational challenges and innovations in clinical development found within the UK & Ireland region.

200+

Attendees

50+

Exhibitors

40+

Speakers

200+

Attendees

50+

Exhibitors

40+

Speakers

See What It's All About

Agenda

  • 10 Jun 2025
  • 11 Jun 2025
Expand All

Streams

Stream one

STREAM A: UK Clinical Trial Landscape Strategy

Stream two

STREAM B: Clinical Technology and Innovation

Stream three

STREAM C: Clinical Trials in Oncology

10 AM

PANEL DISCUSSION: Exploring the landscape for oncology clinical trials in the UK

  • New regulations and guidance around running oncology trials in the UK: what do you need to be aware of?
  • Running clinical trials in conjunction with the NHS: how to ensure your trial is a success
  • Developments in UK cancer research: what’s new in 2025?
  • Working with patients and advocacy groups in the UK: keeping patients at the heart of your oncology trials
  • Assessing the impact of political and economic changes on UK oncology trials
  • The role of the cancer drug fund in accelerating oncology clinical trials in the UK

 

MODERATOR:

Richard Stephens, Chair, Cancer Research Advocates Forum (CRAF-UK)

PANELLISTS:

Emily Pegg, Associate Vice President, Medical, Northern European Hub, Eli Lilly

Further panellists to be confirmed

Speakers

Richard Stephens
Chair, Cancer Research Advocates Forum (CRAF-UK)
Emily Pegg
Associate Vice President, Medical, Northern European Hub, Eli Lilly

10:45 AM

PATIENT STORY: Positive and negative experiences in a patient’s cancer journey: how should clinicians and patients work together?

Speakers

Maria Lawal
Patient Advocate

11:15 AM

Morning refreshments and networking

11:45 AM

Reserved for

Speakers

Stephen Nabarro
Head of Clinical Operations and Data Management, Cancer Research UK

12:15 PM

Available for event sponsor

12:45 PM

CASE STUDY: Conducting a Phase 2 oncology trial in the UK

Speakers

Diane Chisholm
Head of Clinical Operations, Owkin

1:15 PM

Lunch and networking

2:15 PM

PANEL DISCUSSION: Patient centricity in oncology trials: where are the opportunities for the industry and patients?

  • Simple ways of improving patient experience in clinical trials including vocabulary and clear communication
  • Relieving burden on caregivers as well as patients: how can sponsors be more supportive of patients’ families and support network?
  • Working with patients from the beginning of your clinical trial design process
  • Assessing new innovation and technology which can increase support and relieve pressure on oncology patients
  • Where and how can trial sponsors step in to provide long term support for rare cancer patients?
MODERATOR:

Richard Stephens, Chair, Cancer Research Advocates Forum (CRAF-UK)

Speakers

Richard Stephens
Chair, Cancer Research Advocates Forum (CRAF-UK)
Diane Chisholm
Head of Clinical Operations, Owkin
Liz Emmerson
Director Clinical Operations, Blue Earth Therapeutics

3 PM

Available for event sponsor

3:30 PM

Afternoon refreshments and networking

4 PM

Navigating complexities of managing radioligand therapy oncology trials

  • Site selection considerations specific to Radiopharmaceutical Therapy (RPT) clinical trials
  • A sponsor’s perspective of the technical knowledge and expertise required to deliver RPT studies
  • Country specific RPT clinical trial requirements and regulations
  • Challenges with just-in-time supply for RPT investigational products

Speakers

Liz Emmerson
Director Clinical Operations, Blue Earth Therapeutics

4:30 PM

Delivering research in NHS hospitals: the new NIHR Research Delivery Network (RDN)

  • The new NIHR RDN landscape
  • Delivering research in hospital settings
  • Research delivery in partnership

Speakers

Prof Sandip Mitra
NIHR National Lead for Research in NHS Hospital Setting, Deputy Director for NIHR Health Technology Centre for Long Term Conditions (D4D), National Institute for Health and Care Research (NIHR)

5 PM

Chairperson’s closing remarks

Speakers

Richard Stephens
Chair, Cancer Research Advocates Forum (CRAF-UK)

11:45 AM

Optimising patient consent and data management in a shifting geopolitical landscape

This session explores the evolving role of patient consent in clinical trials, focusing on how to maximize its value while ensuring ethical and regulatory compliance. As geopolitical and regulatory landscapes shift, the management of patient samples and data has become increasingly complex. Industry experts will discuss strategies for streamlining consent processes, enhancing transparency, and addressing the challenges of cross-border data and sample handling.

  • The changing nature of patient consent
  • Geopolitical and regulatory impacts on data management
  • Innovative approaches to sample and data tracking
  • Future trends in patient consent and data usage

Speakers

Catherine Mela
Head Precision Medicine Operations, GSK

12:15 PM

Available for event sponsor

12:45 PM

Holding session:

Leveraging novel technologies, digital advances and strategic transformation to accelerate clinical trials, in turn, optimising operational process and elevate the patient experience.

Speakers

Rebecca Jackson
Associate Director, Global Development Systems, Janssen

1:15 PM

Lunch and networking

2:15 PM

PANEL DISCUSSION: Leveraging technology and innovation to support clinical trial execution

  • Adopting innovative technologies to improve clinical trial efficiency
  • Transforming clinical trials using AI driven data analysis
  • Identifying digital tools for patient engagement

 

MODERATOR:

Moderator to be confirmed

 

Speakers

Lara Campana
Senior Vice President, Research and Translational Science, Resolution Therapeutics
Blanka Hezelova
Associate Director, Precision Medicine Scientific Operations, Bioethics Coach, GSK
Joseph Sutton
PhD, Biosample Project Leader and Senior Scientist, Roche

3 PM

Available for event sponsor

3:30 PM

Afternoon refreshments and networking

4 PM

SUSTAINABILITY SPOTLIGHT: Inspiring partnerships and action in sustainable healthcare

Mitigating the environmental impact of clinical trials, in line with the broader imperative to address the interconnected climate and health crises.

Speakers

Dr Fiona Adshead
Chair, Sustainable Healthcare Coalition
Pete Morley
Clinical Sustainability Manager, Novo Nordisk

4:30 PM

CASE STUDY: Abbreviated clinical trials: driving innovation and expediting development

Innovation to reduce the reliance on the global cold chain

Speakers

Karen O’Hanlon
Chief Development Officer, Stablepharma

5 PM

Chairperson’s closing remarks

8 AM

Registration and refreshments

8:45 AM

GlobalData opening remarks

Senior representative, GlobalData

9 AM

OPENING KEYNOTE: Clinical trials in the UK: a cross sector approach to making the UK a destination for clinical research

  • Government priorities: one year on
  • How organisations across the sector are working together to continually improve the system
  • What makes the UK a destination for clinical trials
  • Looking ahead

Speakers

Prof. Lucy Chappell
Chief Scientific Adviser, Department of Health and Social Care, Chief Executive Officer, National Institute of Health Research (NIHR)

9:30 AM

Reserved for event sponsor

10 AM

KEYNOTE PANEL: Where is the clinical trial industry headed this year and beyond?

  • Navigating new regulations around clinical trials smoothly and successfully
  • How do we ensure the UK is an attractive location to run ATMP trials
  • The impact of artificial intelligence: how far can we expect to move forward in the next 12 months?
  • Patient centricity in clinical trials: how can burden be reduced in order to make trials easier for patients to participate in?
  • Technological developments in 2025 and beyond: what changes can we expect to see in the next 3-5 years?

 

MODERATOR:

Moderator to be confirmed

 

PANELLISTS:

Alex Churchill, Deputy Director, Clinical Trials Policy, Department of Health and Social Care

Esther Kitto, Vice President, Clinical Operations, Resolution Therapeutics

Speakers

Alex Churchill
Deputy Director, Clinical Trials Policy, Department of Health and Social Care
Esther Kitto
Vice President, Clinical Operations, Resolution Therapeutics

10:45 AM

Reserved for event sponsor

11:15 AM

Morning refreshments and networking

11:45 AM

MHRA: The new outlook of the Clinical Trials Unit

  • Activities
  • Innovations
  • International collaborations

Speakers

Andrea Manfrin
Deputy Director, Clinical Investigations and Trials, MHRA

12:15 PM

Available for event sponsor

12:45 PM

How can we all maximise the efficiency of study set-up?

  • Learn opportunities for navigating ethics and regulatory reviews quickly
  • Discover the ideal path through study set-up
  • Help NHS sites to follow national standards
  • Explore new UK clinical trials regulations

Speakers

Dr Janet Messer
Director of Approvals, HRA

1:15 PM

Lunch and networking

2:15 PM

PANEL DISCUSSION: Partnering for innovation: a new model to deliver commercial clinical trials at pace and scale

  • The Vaccine Innovation Pathway: delivering results and shaping the future
  • Real-world innovations in site-level delivery
  • Reimagining clinical research delivery: innovative models and collaborative approaches
  • Expanding primary care horizons: commercial trials in the community
  • Driving innovation from industry: lessons learned and future directions

MODERATOR:

Moderator to be confirmed

Speakers

Maria Koufali
Head of UK Vaccine Innovation Pathway, National Institute for Health and Care Research (NIHR)
Sarah Tissington
Regional Director, Clinical Site Management & Monitoring EU/UK, Moderna
Prof Saul Faust
OBE, Director, NIHR Southampton Clinical Research Facility, University of Southampton; Clinical Director, NIHR LCRN Wessex
Dr Rebecca Clark
Partner, Principal Investigator, Fylde Coast Clinical Research and Co-Clinical Lead, UK Vaccine Innovation Pathway

3 PM

Available for event sponsor

3:30 PM

Afternoon refreshments and networking

4 PM

SPONSOR AND SITE RELATIONSHIPS: Excellence in commercial research delivery: the London North West way

  • Overview of geographic, demographic and disease prevalence landscape in LNWH, which serves a largely under-served region of the UK
  • Building the research infrastructure
  • Impact case studies reflecting challenges and opportunities they present
  • Industry partner perspective

Speakers

Divya Manek
Director, Clinical Operations, Eyebiotech
Christiana Dinah
Director, Research and Development, London North West Healthcare NHS Trust

4:30 PM

PANEL DISCUSSION: Unravelling the impact of ICH E6 Revision 3: implementing new standards in good clinical practice

ICH E6 (R3) introduces significant updates to Good Clinical Practice guidelines, emphasizing risk-based quality management, patient centricity, and flexibility in trial design and execution. This panel discussion will address the impact of ICH E6 (R3) on clinical trials, comparing it to the previous ICH E6 (R2), discussing approaches to implementation, and considering varied interpretations among stakeholders.

  • Understand the key changes in ICH E6 (R3) and their implications for clinical trial conduct
  • Explore different approaches to implementing the new guidelines in diverse trial settings
  • Analyse the challenges, opportunities, and interpretations associated with ICH E6 (R3)
  • Highlight meaningful differences between ICH E6 (R2) and ICH E6 (R3) and their practical impacts

MODERATOR:

Moderator to be confirmed

 

PANELLISTS:

Kerri Fuller, Director, Resp/Imm/ID PM Operations, GSK

Further panellists to be confirmed

Speakers

Kerri Fuller
Director, Resp/Imm/ID PM Operations, GSK

5 PM

Chairperson’s closing remarks

NETWORKING DRINKS AND APPLE PRIZE DRAW

Streams

Stream one

Clinical Operations and Outsourcing

Stream two

Clinical Technology and Innovation

11:45 AM

CASE STUDY: Challenges and opportunities in cell therapy clinical development outside oncology

  • Intro into Resolution and our journey from academia to spin out
  • Moving into the clinical space: challenges in developing cell therapy in a space where ATMPs are not widely adopted
  • The role of technology and state-of-the-art analytics to support our cell therapy clinical development

Speakers

Lara Campana
Senior Vice President, Research and Translational Science, Resolution Therapeutics

12:15 PM

Available for event sponsor

12:45 PM

Lunch and networking

2 PM

Clinical trial investigations: looking at the trends and landscape for 2024 and what we can learn from them moving through 2025 and into 2026

  • Overview of global clinical trials for 2024
  • Assessing key sponsors, top interventions and looking at the trial landscape for 2024
  • Looking at key obstacles for terminated trials and evaluation of completed trials which have achieved endpoint status

Speakers

Priya Ravisekara
Senior Analyst, GlobalData

2:30 PM

AI in clinical trials: assessing opportunities and challenges in developing an AI strategy

  • How AI and digitalisation can support streamlining of clinical operations and improve efficiency
  • Simple ways to implement tools such as GPT and GenAI in your trial
  • Where can AI be utilized to minimize workloads and increase overall output?
  • The regulatory landscape in the UK for the use of AI in clinical trials: what do you need to know?
  • Key limitations of GenAI and how these impact its potential uses for clinical trials in the UK

Speakers

Blanka Hezelova
Associate Director, Precision Medicine Scientific Operations, Bioethics Coach, GSK

8 AM

Registration and refreshments

8:50 AM

Chairperson’s opening remarks

9 AM

KEYNOTE PRESENTATION: WHO’s clinical trial guidance: what do I need to know

  • Strengthening regulatory and ethical frameworks and ensuring trials follow global standards and Good Clinical Practice
  • Building capacity and infrastructure, training researchers and enhancing facilities for high-quality trial execution
  • Promoting data transparency and global collaboration, registering trials and sharing data to improve research outcomes
  • Streamlining approval processes, speeding up trial initiation for urgent health needs while maintaining safety and compliance

Speakers

Vasee Moorthy
Senior Advisor, R&D, World Health Organization

9:30 AM

Available for event sponsor

10 AM

The role of R&D in unlocking economic growth and improving population health

  • The investment value of R&D in supporting a geographic spread of research-intensive NHS Trusts
  • The virtuous circle between foreign direct investment, research intensive NHS Trusts and accelerated patient access
  • The role of R&D and research intensive Trusts in re-baselining the standard of care

Speakers

Jagtar Dhanda
Director of Policy Advocacy and Government Affairs, BMS

10:30 AM

Available for event sponsor

11 AM

Morning refreshments and networking

11:45 AM

Patient involvement and engagement, how well are you doing this?

  • Discussing the collaboration that must exist between all parties (patients, coordinators, doctors) in order to have a successful trial
  • Importance of good communication to the patients and how this can streamline trial timelines
  • Exploring how patients could, and should, be influencing decisions and the R&D process before study start-up

Speakers

Amelia Hursey
Strategic Director, Parkinson Europe

12:15 PM

Available for event sponsor

12:45 PM

Lunch and networking

2 PM

Navigating the complexities of running clinical trials both home and away: strategies for success

  • Recruitment strategies: how Lilly selects countries for clinical trials
  • Criteria and processes used by Lilly to recruit and select countries
  • Key factors influencing country selection
  • Performance comparison: UK vs. Other Countries
  • Sharing experiences and lessons from conducting trials in the UK
  • Success stories and challenges faced

Speakers

Emily Pegg
Associate Vice President, Medical, Northern European Hub, Eli Lilly
Victoria Bhui
Associate Director, Investigator Engagement, Eli Lilly

2:30 PM

PANEL DISCUSSION: Current operational challenges in running commercial clinical trials in the UK/IE: the need for increasing our attractiveness globally

  • Ambition for the UK and the current status
  • Site set up: the need for research ready sites
  • Site recruitment: increasing our say do ratio
MODERATOR:

Laura Clifton Hadley, Associate Director, Clinical Operations, BMS

 

Speakers

Laura Clifton Hadley
Associate Director of Clinical Operations, BMS
Chris Cannaby
Clinical Operations Manager Lead, MSD
Saeeda Bashir
Head, Clinical Trials Policy and Programmes, Department of Health and Social Care
Esther Kitto
Vice President, Clinical Operations, Resolution Therapeutics
Rajinder Sidhu
Associate Director, Research Governance and Operations, UCLH

3 PM

Afternoon refreshments, networking, and Apple Prize Draw

3:30 PM

Advancing diversity in clinical research

  • Policy
  • Industry engagement
  • Community engagement
  • Media

Speakers

Dr Suki Balendra
Director, Strategic Partnerships, Paddington Life Sciences and Director, North West London Clinical Trials Alliance

4 PM

ROUNDTABLE SESSIONS

During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table lead/host and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

ROUNDTABLE 1: TBD

Kerri Fuller, Director, Resp/Imm/ID PM Operations, GSK

 

ROUNDTABLE 2: Innovative approaches to support sites facilitate study implementation including EHR data mining, eISF, and SSO login

Marie Lefebvre, Local Innovation Lead, Sanofi

 

ROUNDTABLE 3: The role of lived experience in clinical trials: meaningful patient engagement in clinical trials is vital to develop impactful and relevant outcomes

Cameron Keighron, Project Coordinator, International Diabetes Federation of Europe and Trials@Home consortium member, Patient Advocate

 

 

Speakers

Kerri Fuller
Director, Resp/Imm/ID PM Operations, GSK
Marie Lefebvre
Local Innovation Lead, Sanofi
Cameron Keighron
Project Coordinator, International Diabetes Federation of Europe and Trials@Home consortium member, Patient Advocate

5 PM

Close of conference

END OF CONFERENCE

Speakers

Select a speaker to learn more

Back
Prof. Lucy Chappell
Chief Scientific Adviser, Department of Health and Social Care, Chief Executive Officer, National Institute of Health Research (NIHR)

Professor Lucy Chappell FMedSci is the Chief Scientific Adviser for the Department of Health and Social Care (DHSC), with overall responsibility for the department’s research and development, including the National Institute for Health and Care Research (NIHR), the government’s major funder of clinical, public health, social care and translational research.

Reporting to the Chief Medical Officer, the Chief Scientific Adviser provides science advice and analysis to ministers across the range of health topics and is involved in cross-government science policy.

Professor Chappell is Professor of Obstetrics at King’s College London, Honorary Consultant Obstetrician at Guy’s and St Thomas’ NHS Foundation Trust and an NIHR Senior Investigator. She will undertake the Chief Scientific Adviser role on secondment into government, while continuing some of her clinical and academic work.

DHSC Chief Scientific Adviser

Responsibilities include:

  • overall responsibility for the Department of Health and Social Care’s (DHSC) research policies and budget, including being head of the National Institute for Health and Care Research (NIHR)
  • supporting analysis and evidenced-based decision-making capacity in the department
  • working with Chief Scientific Advisers across government to maximise the impact of science to benefit the UK population

Session Details:

OPENING KEYNOTE: Clinical trials in the UK: a cross sector approach to making the UK a destination for clinical research

2025-06-10, 9:00 AM

View In Agenda
Next speaker
Back
Andrea Manfrin
Deputy Director, Clinical Investigations and Trials, MHRA

Andrea is an academic, consultant, for-profit/non-profit organisations and entrepreneur with over 30 years of international experience in the healthcare sector, specifically focusing on pharmacy, the pharmaceutical industry, health services and pedagogic research. Andrea's goal is to provide better outcomes for everybody: patients, providers, and payers. He provides vision and strategic direction as a leader of small and large research teams from different cultural backgrounds. Andrea offers a unique combination of entrepreneurship and academic rigour, allowing him to succeed in various challenging projects.

Key accomplishments
• Co-led the conceptualisation of the Biomedical Evidence baSed Trans-disciplinary (BEST) health research institute, which focuses on people's health, linking basic and translational investigations from bench to bed to home.
• Led the creation of a multidisciplinary research method and statistical analysis unit (RMSAU), which supports the development of randomised controlled trials in Medicine, Dentistry, Pharmacy Practice, Health Services Research and Pedagogy.
• Co-founder of the Pedagogic Interest Group (PIG), which supports academics in research, widens participation and welcomes early career researchers who contribute to the next REF and students' experience.
• Created an innovative and bespoke pharmacist-led intervention using a patient-reported outcome measure (PROM) subject to an intellectual property right.
• Developed and led a national research project: a novel, cost-effective intervention in primary care that has changed policy and practice, allowing the government to allocate 36 million Euros to fund such services.
• Lead author of a scientific manuscript which is in the top 5% of all research outputs (n=26,673,263) ever tracked by Altmetric.
• Led an academic module, changing team culture and reducing student attrition by 93%.
• Managed a re-engineering process for improving efficiency and time management whilst optimising costs in a retail pharmacy business; the business achieved a return on investment of 52%.
• Created a pharmacy business from scratch and implemented sales and marketing strategies, achieving a return on investment of 900%.

Skills: statistical analysis and data mining, data presentation, health services research, clinical trials, business management, economics.

Research interests: health services research, clinical trials, outcomes research, effectiveness and cost-effectiveness of pharmacist-led interventions, pedagogic research, active learning, and data modelling.

Session Details:

MHRA: The new outlook of the Clinical Trials Unit

2025-06-10, 11:45 AM

View In Agenda
Next speaker
Back
Alex Churchill
Deputy Director, Clinical Trials Policy, Department of Health and Social Care

Session Details:

KEYNOTE PANEL: Where is the clinical trial industry headed this year and beyond?

2025-06-10, 10:00 AM

View In Agenda
Next speaker
Back
Jagtar Dhanda
Director of Policy Advocacy and Government Affairs, BMS

Session Details:

The role of R&D in unlocking economic growth and improving population health

2025-06-11, 10:00 AM

View In Agenda
Next speaker
Back
Laura Clifton Hadley
Associate Director of Clinical Operations, BMS

Laura Clifton-Hadley is an Associate Director of Clinical Operations based in the UK. She leads all clinical trial and late development activities across the Bristol Myers Squibb portfolio. Laura is an experienced leader, with experience in all phases of trials and therapeutic areas. Prior to BMS, she worked as the head of haematology and brain trials at University College London. She has more than 14 years of clinical operations experience, and more than 12 years of line management experience. She sits on various UK and IE industry bodies/government bodies to promote/facilitate commercial clinical research and to ensure that we are bringing the right studies to the UK and IE.
Laura received her PhD in microbiology from the University of Reading. She also holds an honours degree in microbiology and virology from the University of Warwick.

Session Details:

PANEL DISCUSSION: Current operational challenges in running commercial clinical trials in the UK/IE: the need for increasing our attractiveness globally

2025-06-11, 2:30 PM

View In Agenda
Next speaker
Back
Catherine Mela
Head Precision Medicine Operations, GSK

Accomplished pharmaceutical development strategic business leader, empowering collaborative partnerships to achieve their shared goals and objectives. Motivated to ensure scientific strategy and operational delivery align to ensure every human sample collected contributes to understanding of biology, medicines and disease. Experience of driving operational and scientific efficiencies by development and use of new digital tools, system connectivity and data interpretation, whilst ensuring compliance to global regulations.

Session Details:

Optimising patient consent and data management in a shifting geopolitical landscape

2025-06-10, 11:45 AM

View In Agenda
Next speaker
Back
Liz Emmerson
Director Clinical Operations, Blue Earth Therapeutics

Session Details:

PANEL DISCUSSION: Patient centricity in oncology trials: where are the opportunities for the industry and patients?

2025-06-10, 2:15 PM

Session Details:

Navigating complexities of managing radioligand therapy oncology trials

2025-06-10, 4:00 PM

View In Agenda
Next speaker
Back
Victoria Bhui
Associate Director, Investigator Engagement, Eli Lilly

Victoria has worked at Eli Lilly and Company for 16 years across drug safety and clinical operations. In her current role, she leads a team of Clinical Research professionals who work to identify, evaluate, and set up investigator sites across the UK and Nordics. They are responsible for delivery of patients into trials, by forging close site relationships, across the full Lilly portfolio. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are advancing new discoveries to address some of the world's most significant health challenges.

Session Details:

Navigating the complexities of running clinical trials both home and away: strategies for success

2025-06-11, 2:00 PM

View In Agenda
Next speaker
Back
Blanka Hezelova
Associate Director, Precision Medicine Scientific Operations, Bioethics Coach, GSK

Session Details:

PANEL DISCUSSION: Leveraging technology and innovation to support clinical trial execution

2025-06-10, 2:15 PM

Session Details:

AI in clinical trials: assessing opportunities and challenges in developing an AI strategy

2025-06-11, 2:30 PM

View In Agenda
Next speaker
Back
Stephen Nabarro
Head of Clinical Operations and Data Management, Cancer Research UK

Session Details:

Reserved for

2025-06-10, 11:45 AM

View In Agenda
Next speaker
Back
Dr Suki Balendra
Director, Strategic Partnerships, Paddington Life Sciences and Director, North West London Clinical Trials Alliance

Suki Balendra a senior leader in the NHS with a 20-year background in facilitating, growing, and promoting health research in the U.K.  She has substantial, in-depth experience across sectors including industry, academia, NHS, and central government.

She is currently the Director of Strategic Partnerships for Imperial College Healthcare NHS Trust in Northwest London. She leads the strategic work with the Life sciences industry in the region with an emphasis on a new life sciences cluster in Paddington. Suki created and leads the North West London Clinical Trials Alliance. She started her career in the Biotechnology Industry at Abbott Diagnostics Ltd. Within a Good manufacturing practice (GMP) environment she worked on several operational projects to improve efficiency, cost, and reproducibility.

In 2018 she was seconded to the Office of Life Sciences within the Department of Business and Industrial Strategy. where she attracted and negotiated new business to increase the UK’s market share of health and care research activity. During the pandemic she provided operational leadership to the NHS covid vaccine research response in Northwest London.

Suki has PhD from the University of Warwick, and she is accredited to black belt in Lean Six Sigma. She is a passionate advocate for UK PLC as the number one destination to conduct clinical trials.

Session Details:

Advancing diversity in clinical research

2025-06-11, 3:30 PM

View In Agenda
Next speaker
Back
Saeeda Bashir
Head, Clinical Trials Policy and Programmes, Department of Health and Social Care

Session Details:

PANEL DISCUSSION: Current operational challenges in running commercial clinical trials in the UK/IE: the need for increasing our attractiveness globally

2025-06-11, 2:30 PM

View In Agenda
Next speaker
Back
Emily Pegg
Associate Vice President, Medical, Northern European Hub, Eli Lilly

An experienced executive leader within the pharmaceutical industry with a clear focus on and passion for developing high performing cross-functional teams who work without barriers. Highly inclusive yet decisive, adaptable and with a track record of high quality delivery whilst motivating and inspiring the teams around me.

A GMC registered, NHS trained medical doctor with pharmaceutical industry experience across a broad range of therapeutic areas working with both pre-launch and in-market products in the UK and Europe. Known for being commercially astute and a strong cross-functional worker with 10 years of management experience up to a team size of 120 striving always to create a rewarding, high energy environment for my teams.

Session Details:

Navigating the complexities of running clinical trials both home and away: strategies for success

2025-06-11, 2:00 PM

Session Details:

PANEL DISCUSSION: Exploring the landscape for oncology clinical trials in the UK

2025-06-10, 10:00 AM

View In Agenda
Next speaker
Back
Dr Rebecca Clark
Partner, Principal Investigator, Fylde Coast Clinical Research and Co-Clinical Lead, UK Vaccine Innovation Pathway

Dr Rebecca Clark is a Partner at Fylde Coast Clinical Research at Layton Medical Centre, a dedicated commercial trials centre in Blackpool. She is a highly experienced trialist with over 70 Phase II/III clinical trials conducted over the last 13 years, with multiple studies as Chief Investigator in the therapy areas of vaccines, obesity medicine, cardiovascular medicine, asthma and diabetes. She holds a number of senior leadership roles including co-clinical lead for the UK Vaccine Innovation Pathway, a UK clinical trials accelerator.

Fylde Coast Clinical Research at Layton Medical Centre recruits amongst the highest number of commercial participants across the NHS in England and was in the top 1% of NHS recruiting sites when compared with all 637 sites across both primary and secondary care in 22/23. Study participant retention rates exceeded 99%. Her site regularly achieves UK FPV and she is renowned for accelerated set up and recruitment timelines, experience she is now bringing to her role in the UK VIP.

Fylde Coast Clinical Research currently holds contracts with Eli Lilly, Moderna, Astra Zeneca, Roche, Amgen, Merck, Novo Nordisk and GSK, with whom they are members of the PEER preferred site network.

Dr Clark continues to be recognised nationally for her excellence in clinical trial delivery, being a former recipient of the Gold Award for Clinical Site of the Year at the Pharmatimes International Clinical Researcher of the Year.

 

Session Details:

PANEL DISCUSSION: Partnering for innovation: a new model to deliver commercial clinical trials at pace and scale

2025-06-10, 2:15 PM

View In Agenda
Next speaker
Back
Kerri Fuller
Director, Resp/Imm/ID PM Operations, GSK

Session Details:

ROUNDTABLE SESSIONS

2025-06-11, 4:00 PM

Session Details:

PANEL DISCUSSION: Unravelling the impact of ICH E6 Revision 3: implementing new standards in good clinical practice

2025-06-10, 4:30 PM

View In Agenda
Next speaker
Back
Dr Fiona Adshead
Chair, Sustainable Healthcare Coalition

Fiona chairs the Sustainable Healthcare Coalition that inspires partnerships and action on sustainable healthcare. She also works as an independent expert advisor and board member for national and global organisations on wellbeing and sustainability.

She is a high-profile wellbeing and public health leader with a track record of reframing thinking and developing innovative strategy and programmes at the heart of business and government. Her previous roles include Deputy Chief Medical Officer and Director General in the UK Government, Director of Chronic Disease and Health Promotion at the World Health Organisation and Bupa’s Chief Wellbeing Officer.

Fiona is a visiting Professor at UCL and is a Senior Associate at Cambridge Institute for Sustainability Leadership.  Fiona’s recent board roles include Fresenius ESG Advisory Board, My Green Lab, British Land’s Sustainability Advisory Panel, Marks and Spencer’s Sustainable Retail Advisory Board, and Business in the Community’s Wellbeing Leadership Team. Fiona is a member of the Health System Taskforce of the Sustainable Markets Initiative.

Session Details:

SUSTAINABILITY SPOTLIGHT: Inspiring partnerships and action in sustainable healthcare

2025-06-10, 4:00 PM

View In Agenda
Next speaker
Back
Dr Janet Messer
Director of Approvals, HRA

Experienced strategic leader with extensive experience of operations, business transformation and introducing digital systems. Systems-thinker with focus on delivering cross-sector improvement. Deep knowledge of health and care research regulation and governance.

Session Details:

How can we all maximise the efficiency of study set-up?

2025-06-10, 12:45 PM

View In Agenda
Next speaker
Back
Rebecca Jackson
Associate Director, Global Development Systems, Janssen

My leadership strength lies at the intersection of my love of health sciences and a passion for technology. Pushing the boundaries of innovation and leveraging deep industry knowledge, I harness digital advancements and technology’s diverse potential to address industry challenges and provide cutting-edge solutions. Shaping the future of life sciences with forward-thinking strategies and a commitment to excellence, I lead digital transformation strategies which accelerate clinical trials, optimize operational process and elevate the patient and user experience. Through collaboration, fostering synergies between stakeholders and building high performing teams, I champion the integration of AI, data science and advanced technologies to drive adoption for meaningful, sustainable change.

A 20-year technology career within healthcare and life sciences has given me a unique collection of experience, background, networks and knowledge. I use it to lead the adoption, process optimization, and infrastructure development necessary for sustainable innovation, scale and growth.

Key expertise:

• Proven digital innovation and transformation leader whose competencies traverse geographies, resource limits and technical maturity to deliver novel solutions that enable fast, precise decision-making, enhance quality, maximize efficiency, and improve patient safety
• People leadership and mentoring with a unique ability to build diverse, motivated and high performing teams across stakeholder groups and business teams, aligning competing objectives to deliver quality results
• In-depth knowledge of the R&D value chain from the perspectives of Sponsors, Academia, CROs, Vendors, and Patients
• Data governance covering acquisition, transformation, ingestion, standards, interoperability, visualisation and ALCOA++ landscapes and architecture
• Validation and compliance specialist, adept at navigating the regulatory and ethical landscape governing quality, security, privacy, technology and data integrity
• Recognised industry expert, a sought-after conference speaker/facilitator, and active member of global industry initiatives (Vulcan, IMI, TUFTS, EHR2Sponsor)
• Robust operational competencies including contract negotiation and language, governance, risk management, sales, marketing, operations, lecturing, training in addition to exceptional business acumen and communication skills

Session Details:

Holding session:

2025-06-10, 12:45 PM

View In Agenda
Next speaker
Back
Christiana Dinah
Director, Research and Development, London North West Healthcare NHS Trust

• Fellow of the Royal College of Ophthalmologists
• Medical Retina Sub-specialist in a busy, multi-cultural teaching hospital
• Strong academic background in medical retina with expertise in commercial and non-commercial clinical trials
• Teacher and trainer committed to clinical excellence

Session Details:

SPONSOR AND SITE RELATIONSHIPS: Excellence in commercial research delivery: the London North West way

2025-06-10, 4:00 PM

View In Agenda
Next speaker
Back
Sarah Tissington
Regional Director, Clinical Site Management & Monitoring EU/UK, Moderna

Session Details:

PANEL DISCUSSION: Partnering for innovation: a new model to deliver commercial clinical trials at pace and scale

2025-06-10, 2:15 PM

View In Agenda
Next speaker
Back
Chris Cannaby
Clinical Operations Manager Lead, MSD

Session Details:

PANEL DISCUSSION: Current operational challenges in running commercial clinical trials in the UK/IE: the need for increasing our attractiveness globally

2025-06-11, 2:30 PM

View In Agenda
Next speaker
Back
Prof Sandip Mitra
NIHR National Lead for Research in NHS Hospital Setting, Deputy Director for NIHR Health Technology Centre for Long Term Conditions (D4D), National Institute for Health and Care Research (NIHR)

Innovation-driven clinician and an enterpreneurial enthusiast based at the Manchester Academy of Health Sciences Centre, Manchester University Hospitals. Recognised as an influential health technology leader with major contributions to innovation in healthcare technology, dialysis and delivery systems.

Passionate about transforming clinical services and patient pathways through enabling technology.

In various leadership roles as Deputy Director of NIHR MedTech Cooperative Devices for Dignity, Vice Chair for EUDIAL, ERA-EDTA, Chair of the Haemodialysis Study group for UK Kidney Research Consortium. Driving safe and value based health care with national organisations as CQC Speciality Advisor, and as Clinical Reference Group Member for NHS England.

Managing a diverse portofolio of translational clinical academic research with a global network of collaborators. A trainer, educator and mentor for health professionals at the University of Manchester. Several publications, patents, authored book chapters and media reports of the work in the field.

Session Details:

Delivering research in NHS hospitals: the new NIHR Research Delivery Network (RDN)

2025-06-10, 4:30 PM

View In Agenda
Next speaker
Back
Maria Koufali
Head of UK Vaccine Innovation Pathway, National Institute for Health and Care Research (NIHR)

As a seasoned leader in the life sciences sector, I possess extensive experience in strategy development, innovation management, and the successful delivery of complex national-level programs. My career highlights a proven ability to lead transformative initiatives, building high-impact partnerships, and driving innovation across the health and care research landscape in the UK.

Key Career Achievements:
Established the UK Vaccine Innovation Pathway: Delivered the first UK Clinical Trials Delivery Accelerator in collaboration with DHSC, NIHR, NHSE, UKHSA, and Devolved Administrations. Fostered a strategic partnership with Moderna, supporting the rapid development of vaccines and national healthcare priorities.

Executive Leadership in Innovation: First national Research & Innovation Director to receive the Nye Bevan Award in Executive Health Leadership, following an intensive KPMG program, preparing for board-level national roles.

Genomics Leadership: Developed and executed a regional strategy for research and innovation in genomics across the East of England, with a focus on integrating genomic testing for cancer and rare diseases into clinical pathways.

Commercial Success in R&D: Led a £3M annual commercial research portfolio at Nottingham University Hospitals NHS Trust, spearheading transformational infrastructure projects and attracting significant external funding for research and innovation.

Session Details:

PANEL DISCUSSION: Partnering for innovation: a new model to deliver commercial clinical trials at pace and scale

2025-06-10, 2:15 PM

View In Agenda
Next speaker
Back
Diane Chisholm
Head of Clinical Operations, Owkin

Session Details:

CASE STUDY: Conducting a Phase 2 oncology trial in the UK

2025-06-10, 12:45 PM

Session Details:

PANEL DISCUSSION: Patient centricity in oncology trials: where are the opportunities for the industry and patients?

2025-06-10, 2:15 PM

View In Agenda
Next speaker
Back
Pete Morley
Clinical Sustainability Manager, Novo Nordisk

Session Details:

SUSTAINABILITY SPOTLIGHT: Inspiring partnerships and action in sustainable healthcare

2025-06-10, 4:00 PM

View In Agenda
Next speaker
Back
Amelia Hursey
Strategic Director, Parkinson Europe

Amelia joined the Parkinson’s Europe  team in Jan 2022 as Research Manager. Since then she has developed Parkinson’s Europe’s Research Strategy, embedding a Research Steering Group into the organisation and helping to increase the presence of Parkinson’s Europe in the clinical research world. She is also focused on bringing new initiatives to the table, such as the Parkinson’s Europe’s Engagement Network, which better connects the Parkinson’s

community with research across Europe. Parkinson’s Europe is now a partner member of EUPATI and the Critical Path for Parkinson’s as part of this action.

She has been working in the field of Neurodegenerative research since 2009 and is a Patient Organisations board member with EUPATI since Sept 2023.

She previously worked for the UK NIHR’s DeNDRoN delivering clinical trials and then at Parkinson’s UK from July 2015 as Research Participation Lead.  She was responsible for initiatives to increase research participation for people affected by Parkinson’s, health care professionals and researchers, and created the innovative Parkinson’s UK Take Part Hub and co-produced the Staying Connected toolkit in collaboration with the HRA UK.

Session Details:

Patient involvement and engagement, how well are you doing this?

2025-06-11, 11:45 AM

View In Agenda
Next speaker
Back
Maria Lawal
Patient Advocate

Session Details:

PATIENT STORY: Positive and negative experiences in a patient’s cancer journey: how should clinicians and patients work together?

2025-06-10, 10:45 AM

View In Agenda
Next speaker
Back
Lara Campana
Senior Vice President, Research and Translational Science, Resolution Therapeutics

Experienced scientist, specialised in inflammation and tissue repair, with a demonstrated history of delivering ambitious projects in the research industry. Skilled in various lab techniques, including cell culture and flow cytometry. Holder of a Doctorate of Philosophy (Ph.D.) focused on Cellular and Molecular Immunology from The Open University and the Vita-Salute San Raffaele University., followed by two post-docs at The University of Edinburgh. Currently highly focused on translating exciting scientific findings on the role of macrophages in tissue repair to the clinic at Resolution Therapeutics.

Session Details:

CASE STUDY: Challenges and opportunities in cell therapy clinical development outside oncology

2025-06-11, 11:45 AM

Session Details:

PANEL DISCUSSION: Leveraging technology and innovation to support clinical trial execution

2025-06-10, 2:15 PM

View In Agenda
Next speaker
Back
Joseph Sutton
PhD, Biosample Project Leader and Senior Scientist, Roche

Joe Sutton is a Biosample Project Leader at Roche based in the UK. He leads the operational activities relating to clinical biosampling including centralised screening, safety and biomarker analysis. In this role, Joe influences PhI/II clinical trial design across oncology, neurology and rare disease indications and ensures biosampling plans and biomarker strategies bring optimal value, insights and patient centricity. Prior to working with Roche, Joe worked as a consultant at A4PBio and as a Senior Pharmacology Scientist at GW Pharmaceuticals. Before joining the pharmaceutical industry, Joe completed academic research focusing on therapeutic resistance mechanisms of prostate cancer at University of Cambridge (CRUK Institute) and for completion of his PhD from Edinburgh Napier University.

Session Details:

PANEL DISCUSSION: Leveraging technology and innovation to support clinical trial execution

2025-06-10, 2:15 PM

View In Agenda
Next speaker
Back
Marie Lefebvre
Local Innovation Lead, Sanofi

Marie Lefebvre is a Local Innovation Lead at Sanofi, specializing in developing and implementing innovative strategies to optimize clinical trials. With a Master's degree in Physiology and Computer Sciences from Poitiers University, Marie brings extensive experience in digital project management and clinical operations to her role. At Sanofi, she leads the development and implementation of the UK Clinical Operation Innovation Road Map, focusing on gap analysis, change management, and the adoption of cutting-edge technologies. Beyond her professional achievements, Marie is passionate about sustainability, serving as a Climate Fresk facilitator and actively participating in various environmental initiatives within the industry.

Session Details:

ROUNDTABLE SESSIONS

2025-06-11, 4:00 PM

View In Agenda
Next speaker
Back
Karen O’Hanlon
Chief Development Officer, Stablepharma

Session Details:

CASE STUDY: Abbreviated clinical trials: driving innovation and expediting development

2025-06-10, 4:30 PM

View In Agenda
Next speaker
Back
Rajinder Sidhu
Associate Director, Research Governance and Operations, UCLH

Rajinder Sidhu is the Associate Director for Research Governance and Operations for University College London Hospitals (UCLH) and University College London (UCL) Joint Research Office.  She leads on the necessary governance, policies, and operations for both the sponsorship of studies at UCL and UCLH (ranging from clinical trials and advanced therapies through to observational and data programmes) and the systems and infrastructures required to host research at UCLH (commercial and non-commercial). Rajinder has over 17 years’ experience in senior operational and governance roles at UCLH/UCL and has led large change programmes to streamline systems and embed leaner ways of working across the organisation.

 

Prior to UCLH/UCL, Rajinder worked for Kings College London, Institute of Psychiatry as a researcher/coordinator for regional research studies into mental health services, and as a manager of international research centres. Rajinder also completed a PhD on consumerism within the NHS at Royal Holloway, University of London.

Session Details:

PANEL DISCUSSION: Current operational challenges in running commercial clinical trials in the UK/IE: the need for increasing our attractiveness globally

2025-06-11, 2:30 PM

View In Agenda
Next speaker
Back
Esther Kitto
Vice President, Clinical Operations, Resolution Therapeutics

An innovative and dynamic VP of Clinical Operations highly proficient in clinical trial drug development, clinical trial operations and regulatory requirements gained within pharmaceutical, biotechnology and CRO industries. A creditable track record in the development of a broad range of investigational medicinal products, including biologics and ATIMPs. A real problem solver with high levels of personal initiative, strong customer focus and impressive leadership skills.

Esther Kitto: Clinical Operations, Clinical Development, Strategic Operations, Operational Oversight, Global Project Management, CRO and Vendor Management, Outsourcing, Training and Development, MHRA and FDA Applications and Submissions, Safety Reporting, Safety Management, Steering Committee/KOL/Advisory Board Meetings, Protocol Development, Medical Writing, Onboarding, Team Building, Leadership, Genetically Modified Organisms, GMO, ATMPs, Business Development, Clinical Development Plans, Hiring, Competency Based Interviewing, Performance Development, Multiple Therapeutic Areas, Gene Therapy, Stem Cell Therapy, Written Communication, Analytical Skills, Computer Literacy, Interpersonal Skills

Session Details:

PANEL DISCUSSION: Current operational challenges in running commercial clinical trials in the UK/IE: the need for increasing our attractiveness globally

2025-06-11, 2:30 PM

Session Details:

KEYNOTE PANEL: Where is the clinical trial industry headed this year and beyond?

2025-06-10, 10:00 AM

View In Agenda
Next speaker
Back
Vasee Moorthy
Senior Advisor, R&D, World Health Organization

Dr. Vasee Moorthy is Senior Advisor, Research for Health Department, WHO Science Division, Geneva, Switzerland. Since 2008, he has held progressively senior roles at WHO in malaria vaccine policy development, Ebola vaccine phase 1-2 trials, global norms in sharing research data and results during public health emergencies, WHO R&D Blueprint for action to prevent epidemics, global consensus on clinical trials policy norms, WHO COVID-19 Research & Innovation Roadmap and the WHO Solidarity Trial of therapeutics supporting clinical trials networks in over 40 Member States in all WHO regions, and most recently, the adoption of resolution (WHA75.8) on clinical trials. Prior to joining WHO, Dr. Moorthy worked as a medical researcher at the University of Oxford, UK (2005-2008); with an NGO, PATH, in USA (2003-2005); running a clinical trials programme at MRC Laboratories in The Gambia (1999-2003), and as a government medical officer in Kwazulu/Natal, South Africa (1996-1997). He received a B.A. and M.A. from the University of Cambridge in Natural Sciences, a B.M.B.Ch medical degree and a Ph.D in malaria immunology and clinical trials both from the University of Oxford.

Session Details:

KEYNOTE PRESENTATION: WHO’s clinical trial guidance: what do I need to know

2025-06-11, 9:00 AM

View In Agenda
Next speaker
Back
Cameron Keighron
Project Coordinator, International Diabetes Federation of Europe and Trials@Home consortium member, Patient Advocate

Session Details:

ROUNDTABLE SESSIONS

2025-06-11, 4:00 PM

View In Agenda
Next speaker
Back
Richard Stephens
Veteran Patient Advocate, Trial Participant, Author, Journal Editor

Richard Stephens has been a patient advocate for 25 years, surviving two cancers and a heart emergency, plus several co-morbidities and late effects. As a patient he has participated in four interventional studies and nine others. As an Advocate he has helped design over 30 more.

Richard Chairs the UK Cancer Research Advocates Forum (formerly the NCRI Consumer Forum) and is the former Chair of BBMRI-ERIC’s Stakeholder Forum. He works with patient groups and advocates, academics and industry, and policy-makers, funders and regulators.  

Richard helped found the AllTrials campaign and useMYdata movement, and he is the founding co-Editor-in-Chief of the Journal of Research Involvement and Engagement. His professional life has included careers in education, journalism and local government.

Next speaker
Back
Divya Chadha Manek
Director, Clinical Operations, Eyebiotech

Divya Chadha Manek both establishs and maintains existing strategic relationships with global and UK life sciences companies. Facilitation is her forte: working collaboratively with companies she advises, guides and connects people so that study sponsors and CROs who deliver research, derive maximum benefit from the support provided by the NIHR - the most integrated health research system in the world. From her roots in commercial research delivery in NHS hospitals, Divya went on to manage a national portfolio of commercial mental health studies before progressing to her current role. With this wealth of experience under her belt she can provide expert advice on how to use the NIHR services to optimise successful delivery of clinical trials in the UK

Next speaker

Advisory Board

Select a member to learn more

Back
Bao Dinh
Global Development Business Operation, Takeda

With over 15 years of experience in Clinical Data Management, Bao leads business strategy and vendor operations for Takeda’s Clinical Data Management, Clinical Data Engineering, and Clinical Data Standards groups, driving organizational growth, managing global FSP partnerships, and enhancing cross-functional collaboration. As a member of the 2024–2025 OCT Advisory Board, Bao brings expertise in clinical outsourcing, strategic vendor partnerships, and RFP process optimization, providing a fresh vision for the organization.

Beyond professional achievements, Bao is dedicated to fostering collaboration and investing in the local community. As a partner of The Town FC and a Silicon Valley angel investor, Bao champions ventures that advance sustainable growth, youth enrichment, and innovation in technology.’

Next
Back
Rosalie Filling
Vice President, Senior Global Head R&D Operations, Endo Pharmaceuticals

In her over 25 years of experience, Rosalie “Rosie” Filling has transformed R&D operations in every company she has worked for, developing clear-cut strategies to help advance clinical trials with high-quality operational execution and scientific excellence.

 

Rosie is the Vice President, Senior Global Head R&D Operations Endo International plc. She is part of the global R&D leadership team and is charged with the coordination and implementation of clinical development strategies for the company’s research and development. She provides strategic direction and oversight of the R&D Operations team, which includes clinical operations, data management, biostatistics, medical writing, clinical supplies, trial master file/inspection readiness and business operations. This integrated team handles the execution of all aspects related to Endo’s clinical trials. Endo has active research and development programs in men’s health, orthopedics, and endocrinology. Beyond these therapeutic areas, the company also has focused development in the areas of sterile injectables and complex generic products.

 

Rosie’s main focus at all times is on the end users—the patients. Bringing new and, at times, life-saving medications to patients drives Rosie’s sense of purpose.

 

Rosie joined Endo from Lupin Pharmaceuticals in Blue Bell, PA where she was Senior Director, Head of Clinical Operations, and built the clinical operations organization to support the US and Global R&D Organization. Prior to Lupin, Rosie spent nearly five years at Teva in Frazer, PA where she was the US site head of Clinical Operations and was responsible for the successful delivery of Inhalation, Women’s Health, and Cardiovascular clinical trials. Earlier in her career, Rosie held various roles at Eisai, MGI Pharma and PPD.

 

Rosie earned her B.S. in Biology with a minor in Chemistry from the University of Pittsburgh.

Next
Back
Kathleen Cohen
Vice President, Clinical Development, Marinus Pharmaceuticals

Kathleen Frenia Cohen is Vice President and Head of Clinical Development Operations at Marinus Pharmaceuticals.  Prior to joining Marinus, she spent 20+ years at PRA Health Sciences in a variety of project management and operational oversite roles. Kathleen graduated from the University of the Science in Philadelphia with a PharmD and completed a post-doctoral fellowship in Pharmacoeconomics and Outcomes Research from Rutgers College of Pharmacy. Kathleen resides in Media, PA.

Next
Back
THOMAS M TREMBLAY
Vice President Of Clinical Development, Trefoil Therapeutics, Inc

Thomas is a registered nurse with both clinical and over 30 years pharmaceutical development experience. His pharmaceutical development experience includes clinical operations, clinical science, clinical development, drug safety and quality. He is currently Vice President of Clinical Development at Trefoil Therapeutics and adjunct faculty at San Francisco State University.

Next
Back
Behtash Bahador
Director, Health Literacy, CISCRP

Behtash Bahador is the Director of Health Literacy at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.

Next

Plan Your Visit

Venue

Hilton Park Lane, London, UK

Accommodation

Arena International Events Group “(Arena”) is aware of numerous third party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings and events attendee lists. For the avoidance of doubt, Arena will only share attendee lists with carefully selected third party partners for event registration purposes. Whilst Arena International Events Group pursues third party agencies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group.

2025 Sponsors

Select a sponsor to learn more

FEATURED SPONSORS

SESSION SPONSORS

DRINKS RECEPTION SPONSOR

EXHIBITORS

co-sponsor

Why partner?

Contact us to become a partner

Partnership Opportunities

We work with you to design a bespoke package to meet your business needs, where you could:

  • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
  • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
    Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
  • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

Event reach

  • 200+ attendees each year
  • 80% attendees C-suite level

 

Take a look at our current sponsors

Resources

       
       
   

Media Centre

Become A Media Partner

See What It's All About

Enquiry

Contact Us

SPONSORSHIP ENQUIRIES

Ben Lloyd-Davis

Head of Healthcare Sponsorship

+44 207866 9497

SPEAKING OPPORTUNITIES

Maya Hudson

Deputy Head of Production

+44 204540 7766

MARKETING ENQUIRIES

Moona Popal

Marketing Manager

DELEGATE ENQUIRIES

Sunny Saikia

VIP Delegate Manager

SPONSORSHIP ENQUIRIES

To enquire about sponsorship opportunities for the conference, please contact:

Ben Lloyd-Davis

Head of Healthcare Sponsorship


+44 207866 9497

SPEAKER ENQUIRIES

To enquire about speaking opportunities for the conference, please contact:

Maya Hudson

Deputy Head of Production


+44 204540 7766